GSK acquires Elsie to unlock oligonucleotide therapeutics [Yahoo! Finance]
Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN)
Company Research
Source: Yahoo! Finance
Elsie Biotechnologies has been at the forefront of oligonucleotide therapeutic development, focusing on increasing potency, reducing toxicity, and optimising delivery to harness the potential of the modality fully. The acquisition is set to enhance GSK's research and development (R&D) in gene modulation. Elsie Biotechnologies offers technologies that can modulate gene expression. This feature is particularly valuable for targeting therapeutic areas that are not responsive to traditional small-molecule drugs or biologics. The integration of Elsie's technologies for the discovery, synthesis and delivery of oligonucleotide into GSK's R&D framework is expected to advance the company's platform capabilities significantly. The move follows a successful initial partnership between the two companies which began in July 2023 and allowed GSK to assess and validate Elsie's technology. GSK's use of AI and machine learning, combined with data from Elsie's platform, aims to develop pre
Show less
Read more
Impact Snapshot
Event Time:
HLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HLN alerts
High impacting Haleon plc American Depositary Shares (Each representing two Ordinary Shares) news events
Weekly update
A roundup of the hottest topics
HLN
News
- Sensodyne maker Haleon to raise stake in China JV [Yahoo! Finance]Yahoo! Finance
- Analysts agree that Kenvue's Neutrogena needs a face-lift [Seeking Alpha]Seeking Alpha
- Haleon plc (NYSE: HLN) had its price target raised by analysts at Morgan Stanley from $9.90 to $10.95. They now have an "overweight" rating on the stock.MarketBeat
- Haleon (LSE:HLN) Eyes Bolt-On M&A and New Product Launches to Drive Growth Despite High Valuation Concerns [Yahoo! Finance]Yahoo! Finance
- Estimating The Fair Value Of Haleon plc (LON:HLN) [Yahoo! Finance]Yahoo! Finance
HLN
Sec Filings
- 9/27/24 - Form 6-K
- 9/27/24 - Form 6-K
- 9/26/24 - Form 6-K
- HLN's page on the SEC website